Literature DB >> 2642713

Analysis of N-RAS exon-1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing.

M Bar-Eli1, H Ahuja, N Gonzalez-Cadavid, A Foti, M J Cline.   

Abstract

Mutations in codons 12 or 13 of the first exon of the N-RAS gene have been reported in myelodysplastic syndromes (MDS) in frequencies that vary between 9% and 40% depending on the techniques used in analysis. Gene amplification and direct sequencing provides the only unambiguous method of detecting those mutations that induce amino acid alterations. Using this technique, we analyzed 21 MDS patients for mutations in exon-1 of N-RAS. Codon 12 mutations substituting aspartic acid (GAT) for glycine (GGT) were found in four cases, and a codon 13 mutation substituting alanine (GCT) for glycine (GGT) was detected in one patient. We conclude that N-RAS exon-1 mutations in one patient. We conclude that N-RAS exon-1 mutations producing amino acid changes occur in about 20% to 25% of MDS cases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642713

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Digital PCR.

Authors:  B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; Z Arlin; S Advani; S L Allen; J Goldman; D Snyder; A Foti; M Cline
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

3.  Transforming genes and chromosome aberrations in therapy-related leukemia and myelodysplastic syndrome.

Authors:  K Inokuchi; N Amuro; M Futaki; K Dan; T Shinohara; S Kuriya; T Okazaki; T Nomura
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

4.  Oncogene expression in primary myelodysplasia: correlation with haematological, karyotypic, and clinical progression.

Authors:  R M Hutchinson; J H Pringle; S C Knight; I Lauder; A Potter; C Jagger
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

5.  Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Authors:  Marta Fernandez-Mercado; Adam Burns; Andrea Pellagatti; Aristoteles Giagounidis; Ulrich Germing; Xabier Agirre; Felipe Prosper; Carlo Aul; Sally Killick; James S Wainscoat; Anna Schuh; Jacqueline Boultwood
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

6.  Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing.

Authors:  S M Grimmond; D Raghavan; P J Russell
Journal:  Urol Res       Date:  1992

7.  Cationic copolymers that enhance wild-type-specific suppression in BNA-clamp PCR and preferentially increase the T m of fully matched complementary DNA and BNA strands.

Authors:  Ami Tachibana; Nahohiro Fujimura; Minoru Takeuchi; Koji Watanabe; Yoko Teruuchi; Tomoaki Uchiki
Journal:  Biol Methods Protoc       Date:  2022-03-30

Review 8.  Existing and emerging technologies for tumor genomic profiling.

Authors:  Laura E MacConaill
Journal:  J Clin Oncol       Date:  2013-04-15       Impact factor: 44.544

Review 9.  FAB classification of myelodysplastic syndromes: merits and controversies.

Authors:  G E Verhoef; S Pittaluga; C De Wolf-Peeters; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

10.  Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing.

Authors:  Olivier Harismendy; Richard B Schwab; Lei Bao; Jeff Olson; Sophie Rozenzhak; Steve K Kotsopoulos; Stephanie Pond; Brian Crain; Mark S Chee; Karen Messer; Darren R Link; Kelly A Frazer
Journal:  Genome Biol       Date:  2011-12-20       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.